🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesSTEP-HFpEF: semaglutide in heart failure with preserved EF — March 2026 Page 7

STEP-HFpEF: semaglutide in heart failure with preserved EF — March 2026

GenomicsKate Wed, Jun 4, 2025 at 7:34 PM 38 replies 1,967 viewsPage 7 of 8
mel_PDX
Member
189
890
Dec 2024
Portland, OR
Nov 9, 2025 at 11:06 AM#31
GenomicsKate said:
Update since I posted: I held at 1.7mg for a further twelve weeks and lost another 4kg slowly, which settles it for me.

I read this differently from GenomicsKate, on substance rather than tone. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

1 1Dr.NateNeph
Reply Quote Save Share Report
SteveThurs
Member
523
2,345
Sep 2024
Wisconsin
Online
Nov 21, 2025 at 1:39 PM#32
GenomicsKate said:
Update since I posted: I held at 1.7mg for a further twelve weeks and lost another 4kg slowly, which settles it for me.

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

References:
[1] Zheng SL, et al. Lancet Diabetes Endocrinol. 2023;11(12):869-879.
Last edited: Nov 21, 2025 at 5:39 PM
50 0PurityPaulOR, MaxMetOK, MounjBrad and 47 others
Reply Quote Save Share Report
NurseLeah_Nash
Member
278
1,234
Sep 2024
Nashville, TN
Dec 3, 2025 at 4:05 PM#33
GenomicsKate said:
Update since I posted: I held at 1.7mg for a further twelve weeks and lost another 4kg slowly, which settles it for me.

Genuinely useful, thank you. I had the facts and not the framework. Adding it to my notes with a link back to this thread.

49 24PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 46 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
SarahChen_PharmD
VIP Member
4,567
22,341
Dec 2023
San Diego, CA
Dec 15, 2025 at 6:24 PM#34

Adding the clinical framing, because it changes how the question reads.

I'm 55 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

8 months later: down 55 lbs, off atorvastatin, A1C from 7.0% to 5.4%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

48 23TinaHashiRN, robert_kc, dan_philly and 45 others
Reply Quote Save Share Report
BariatricNurseD
Senior Member
1,678
7,234
Feb 2024
Dallas, TX
Online
Dec 27, 2025 at 8:36 PM#35
SarahChen_PharmD said:
I'm 55 years old and want to share my perspective on cardiovascular risk as an older member of this community.

Second this.

Last edited: Dec 28, 2025 at 1:36 AM
47 22Dr.EndoIndy, tom_AK, josh_phd_bmore and 44 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register